- Swiss life sciences company Siegfried Holding AG ( OTC:SGFEF ) announced Wednesday that it decided to extend the collaboration with Novavax ( NASDAQ: NVAX ) for the fill & finish process of the U.S. biotech's COVID-19 vaccine.
- Accordingly, the initial agreement, expected to expire in 2022, will continue until the end of 2023, with production at Siegfried's ( OTC:SGFEF ) manufacturing site in Hameln, Germany.
- The contract manufacturer reiterated its 2022 guidance and mid-term outlook even as a separate deal with German COVID-19 vaccine maker BioNTech ( BNTX ) ends at the end of the year.
- The announcement comes after Novavax ( NVAX ) said Tuesday that 1M doses of its protein-based shot were now available in the U.K.
- A study based on self-reported COVID test results indicated that case numbers jumped 30% in England over the past week after a downward trend,
- "We continue to believe in the importance of a diversified national vaccine portfolio to reduce winter pressures on the health service." Novavax ( NVAX ) Chief Executive Stanley Erck remarked.
For further details see:
Novavax, Siegfried extend COVID-19 vaccine production deal